John Barnidge

Jim said in the later innings. Back-office transformation with State Street completing later this year. Front-end improvements using AI and offshore demographics are well advanced.

Jim described AM as well-positioned with transformed platform, strong investment performance, and expanding product suite. Currently focused on organic state but sees consolidation opportunity over time.

Jim noted Ameriprise launched its own interval fund and is pursuing other alternative space opportunities, some with partners and some organic. Market still early for many announced partnerships.

Jim acknowledged large team departures caused short-term outflow exceeding inflow. Highlighted a recent $1.7B recruit. Core organic productivity growth remains the primary driver.

Jim cited Lionstone exit, LDI, and passive repositioning on institutional side. Retail gross sales up but April redemptions higher. Launching new ETFs and interval fund.

Jim described continuous investment in AI dashboards, intelligent automation, and data analytics. Expense savings from transformation reinvested into growth capabilities.

Jim outlined product strategy: active ETFs, SMA model delivery, upcoming interval fund with public/private markets, new hedge fund gaining traction.

Walter confirmed RPS earnings are solid and predictable. Strong sales (time-to-sale P&L impact) offset by investment strategy benefits. Book has good risk-adjusted returns.

Jim acknowledged alternatives platform is at early stages in their channel. Added digital platform with due diligence but expected to remain small relative to ultra-high-net-worth.

Walter cited good trajectory from claims and rate increases, noted $61 million generated in 2024 as a positive. Declined to give exact run rate number.

Yoshizumi noted Tsumitasu attracting broader demographic including affluent older customers using discounted advanced premium option. Dan said Miraito had spectacular 2025 but expects sales to level off in 2026 while medical and Tsumitasu grow.

Max identified three drivers: (1) 130bp lower net premium ratio from Q3 2025 unlock (permanent), (2) lapse/reissue activity releasing reserves on older lower-reserve policies, (3) runoff of high-benefit-ratio WAYS savings block sold 2010-2016.

Virgil emphasized bundling VB with dental and lab products for unified broker experience. On inorganic, said building corporate development discipline but haven't seen attractive acquisition targets that would meaningfully move operations.

Virgil said lab has had profitable quarters but not consistently at scale. Dental needs more growth for profitability. Max clarified one business turned profitable in 2025 but two have not, and target profitability will take a few more years.

Yoshizumi confirmed cancer refresh every 3 years and medical every 2 years, subject to FSA approval.

Yoshizumi confirmed full distribution rollout by end of Q2 with March launch for associates and April for banks/Japan Post.

Max explained Q3 unlock drives larger remeasurement gains while other quarters have smaller true-ups. Favorable claims trends in Japan continue long-term.

Dan acknowledged typical pre-launch sales dip followed by strong growth from new product excitement across distribution channels.

Virgil clarified dental was available in Q4 but service degradation earlier damaged broker trust. Seeing progress in January with regaining confidence.

Minimal exposure: <$15M in alternatives to software, <2% fixed maturities in technology (mostly hardware/data services). ~$50M potentially AI-displaceable names with some moat protection. Long-duration investment philosophy naturally limits tech exposure. AI risk part of investment matrix for years.

EEOC findings non-binding, no litigation filed. Courts have historically ruled AIL agents are properly classified as independent contractors. Company would vigorously defend if challenged.

Acknowledged secular demographic tailwind from growing retiree population. Med Sup has persistent demand from consumers valuing provider choice. Business ebbs and flows with MA competitive dynamics but long-term opportunity strong.

Not capital-constrained today so no sales acceleration. Bermuda improves cash flow conversion timing (GAAP DAC deferral). Provides parent flexibility for M&A or shareholder returns.

Series of transactions: initial small block to establish operations, then in-force blocks plus new business cessions over time to reach 25% of statutory reserves.

Targeting $300-325M from current $410M, bringing debt-to-capital back to historical 3% level (25% total debt/capital at year-end).

Primarily frequency-driven but specialty bandages add severity. Using AI and data analytics to identify potentially fraudulent claims. Working with CMS on mitigation.

Management noted holiday seasonality is normal, Q2/Q3 typically see pickup. Starting strong for 2025 with high correlation between agent count and sales (8% CAGR each at AIL over 3 years).

On track for midyear update. No specific details provided beyond timeline confirmation.

Yanela broke down $150-180M: ~20% lost sales, ~20% higher surrenders, ~60% distribution force financial support (discretionary, tied to suspension period, doesn't carry over). Compounding less than VA runoff since distribution support is period-specific.

Andy declined to dimension specific businesses but outlined strategic framework: large growing markets, differentiated capabilities, industry-leading returns. Japan by far predominant international business. Emerging markets focused on Brazil (record quarter) and Habitat pension business.

Andy explained complementary capabilities: Partners brings primary PE, PRU brings credit and real estate. Partnerships are an important growth tool. Dai-ichi partnership also progressing. Expect more partnership-based growth going forward.

Yanela confirmed Prismic remains important tool. Active pipeline includes balance sheet optimization, new business financing, and third-party blocks. New: first forward flow transaction for U.S. retail fixed annuities launched (small quantities initially).

Andy cited two reform focus areas: lifetime income solutions as DC plan defaults and expanding access to alternatives in retirement plans. Pioneered 'active income' insurance overlay on separately managed accounts. Expanding retail vehicles to ETFs and SMAs.

Andy confirmed organic growth is job #1 and recent changes unlock additional opportunity. M&A can be accelerant but not required. Interested in capability bolt-ons to larger scale opportunities, especially globalizing and building credit/alternatives/real assets positions.

Andy confirmed PGIM is already launching interval funds combining public and private capabilities, expanding both institutionally and on retail side. Referenced J-curve timeline for asset flows and results.

Andy cited DeerPath Capital acquisition as example of complementary inorganic deployment. High bar for inorganic capital, leaning into higher growth and capital-efficient areas.

Charlie confirmed focus on organic growth with selective M&A interest in PGIM, emerging markets, and distribution capabilities.

Deanna noted separation into IM and IP allowing IM to focus on global growth. Recent divestitures focused on nonsynergistic pension assets. Remaining IP businesses considered strategic with ability to contribute to IM growth through cross-selling and relationship leverage.

Joel noted software exposure under 1% of general account with deals underwritten on cash flow basis. Amy cited SMB well-being index showing AI seen as growth driver by small businesses. Own block data shows no negative staffing impact. Almost all SMBs expect wages to stay stable or increase.

Chris noted industry consolidating from approximately 40 recordkeepers toward single digits over next 10 years. Principal as #3 player expects to be a real beneficiary. Focused on organic growth rather than large transactions. Deanna emphasized revenue growth focus over flow metrics.

Kamal explained Barings partnership expands private market expertise with Barings handling origination and Principal handling portfolio management and underwriting. Joel noted 95% of general account managed internally with partnerships augmenting capabilities.

Chris acknowledged more competitors entering PRT market but Principal generates significant business from existing DB client conversions. Historical range maintained. Disciplined on returns with capital deployed elsewhere if targets not met.

Joel noted 50% of alts portfolio in real estate with no transaction activity in Q2. Highly appreciated real estate assets with gains not recognized until sale. Office leasing picking up. Full year VII expected below long-term run rate but improving in second half.

Deanna emphasized current portfolio is well-positioned but will continue to evaluate. Strategic review already led to sizable changes; future pivots where growth isn't materializing.

Chris noted Principal not a large player in governmental retirement. Amy confirmed Specialty Benefits has no government market presence at all.

Meier called auto claims inflation stable versus CPI and housing well positioned, with Demmings citing rate actions in auto and the housing inflation guard (average insured values up 5%) as offsets.

Meier reported nothing significant on frequency, noting continued progress on claims experience across vehicle service contracts and the GAP program.

Demmings and Meier cited AI in premium tech support, dealer sales, device care center robotics, and personalized product targeting.

Meier quantified 2025 PYD at $113M and said the $130M combined headwind (PYD + home warranty investment) is what underlying growth overcomes.

Meier framed $140M as 2026-specific and growing thereafter if more clients are added; long-term agreement beyond typical 3-5 year deals.

Demmings declined to quantify a dollar impact but confirmed tariffs-through-year assumption and framed impact as manageable; Meier detailed parts share math for Auto.

Demmings normalized expense ratio to flat YoY: $11M higher reinsurance = 110bps, remainder from cat claims handling.